Literature DB >> 21242007

Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease.

Qian Zhou1, Christoph Gensch, James K Liao.   

Abstract

ROCKs are important regulators of the actin cytoskeleton. Because changes in the actin cytoskeleton underlie vascular contractility and remodeling, inflammatory cell recruitment, and cell proliferation, it is likely that the Rho/ROCK pathway will play a central role in mediating vascular function. Indeed, increased ROCK activity is observed in cerebral and coronary vasospasm, hypertension, vascular inflammation, arteriosclerosis, and atherosclerosis. Recent experimental and clinical studies suggest that inhibition of ROCK could be a promising target for the treatment of cardiovascular disease. For example, inhibition of ROCK might be the underlying mechanism by which statins or HMG-CoA reductase inhibitors exert their therapeutic benefits beyond cholesterol reduction. In this review we summarize current understanding of the crucial role of RhoA/ROCK pathway in the regulation of vascular function and discuss its therapeutic potential in the treatment of atherosclerosis and vascular disease.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21242007      PMCID: PMC3080120          DOI: 10.1016/j.tips.2010.12.006

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  74 in total

Review 1.  Rho kinase, a promising drug target for neurological disorders.

Authors:  Bernhard K Mueller; Helmut Mack; Nicole Teusch
Journal:  Nat Rev Drug Discov       Date:  2005-05       Impact factor: 84.694

2.  Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial.

Authors:  Masato Shibuya; Shunsaku Hirai; Minoru Seto; Shin-ichi Satoh; Eiichi Ohtomo
Journal:  J Neurol Sci       Date:  2005-07-11       Impact factor: 3.181

3.  PSGL-1 and mTOR regulate translation of ROCK-1 and physiological functions of macrophages.

Authors:  Richard Fox; Thomas Q Nhan; G Lynn Law; David R Morris; W Conrad Liles; Stephen M Schwartz
Journal:  EMBO J       Date:  2007-01-24       Impact factor: 11.598

Review 4.  Pleiotropic effects of statins. - Basic research and clinical perspectives -.

Authors:  Qian Zhou; James K Liao
Journal:  Circ J       Date:  2010-04-15       Impact factor: 2.993

5.  Increased leukocyte rho kinase (ROCK) activity and endothelial dysfunction in cigarette smokers.

Authors:  Takayuki Hidaka; Takaki Hata; Junko Soga; Yuichi Fujii; Naomi Idei; Noritaka Fujimura; Yasuki Kihara; Kensuke Noma; James K Liao; Yukihito Higashi
Journal:  Hypertens Res       Date:  2010-02-05       Impact factor: 3.872

6.  PKC and Rho in vascular smooth muscle: activation by BOXes and SAH CSF.

Authors:  Gail J Pyne-Geithman; Sunil G Nair; Danielle N Caudell; Joseph F Clark
Journal:  Front Biosci       Date:  2008-01-01

Review 7.  Rho GTPases and the regulation of endothelial permeability.

Authors:  Beata Wojciak-Stothard; Anne J Ridley
Journal:  Vascul Pharmacol       Date:  2002-11       Impact factor: 5.773

8.  Rho-associated kinase of chicken gizzard smooth muscle.

Authors:  J Feng; M Ito; Y Kureishi; K Ichikawa; M Amano; N Isaka; K Okawa; A Iwamatsu; K Kaibuchi; D J Hartshorne; T Nakano
Journal:  J Biol Chem       Date:  1999-02-05       Impact factor: 5.157

9.  Upregulation of Rho-kinase (ROCK-2) expression and enhanced contraction to endothelin-1 in the mesenteric artery from lipopolysaccharide-treated rats.

Authors:  Kansu Büyükafşar; Onur Arikan; Mustafa Ark; Havva Kubat; Elif Ozveren
Journal:  Eur J Pharmacol       Date:  2004-09-13       Impact factor: 4.432

10.  A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes.

Authors:  T Leung; E Manser; L Tan; L Lim
Journal:  J Biol Chem       Date:  1995-12-08       Impact factor: 5.157

View more
  59 in total

1.  Circulating endothelin-1 alters critical mechanisms regulating cerebral microcirculation.

Authors:  Giuseppe Faraco; Ana Moraga; Jamie Moore; Joseph Anrather; Virginia M Pickel; Costantino Iadecola
Journal:  Hypertension       Date:  2013-08-19       Impact factor: 10.190

Review 2.  Rho-kinase: regulation, (dys)function, and inhibition.

Authors:  Ehsan Amin; Badri Nath Dubey; Si-Cai Zhang; Lothar Gremer; Radovan Dvorsky; Jens M Moll; Mohamed S Taha; Luitgard Nagel-Steger; Roland P Piekorz; Avril V Somlyo; Mohammad R Ahmadian
Journal:  Biol Chem       Date:  2013-11       Impact factor: 3.915

Review 3.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

4.  ROCK Inhibition Extends Passage of Pluripotent Stem Cell-Derived Retinal Pigmented Epithelium.

Authors:  Roxanne H Croze; David E Buchholz; Monte J Radeke; William J Thi; Qirui Hu; Peter J Coffey; Dennis O Clegg
Journal:  Stem Cells Transl Med       Date:  2014-07-28       Impact factor: 6.940

5.  Discovery of vascular Rho kinase (ROCK) inhibitory peptides.

Authors:  Reza Abbasgholizadeh; Hua Zhang; John W Craft; Robert M Bryan; Steven J Bark; James M Briggs; Robert O Fox; Anton Agarkov; Warren E Zimmer; Scott R Gilbertson; Robert J Schwartz
Journal:  Exp Biol Med (Maywood)       Date:  2019-05-27

6.  Leukocyte RhoA exchange factor Arhgef1 mediates vascular inflammation and atherosclerosis.

Authors:  Maria Luigia Carbone; Gilliane Chadeuf; Sandrine Heurtebise-Chrétien; Xavier Prieur; Thibault Quillard; Yann Goueffic; Nathalie Vaillant; Marc Rio; Laure Castan; Maxim Durand; Céline Baron-Menguy; Julien Aureille; Juliette Desfrançois; Angela Tesse; Raul M Torres; Gervaise Loirand
Journal:  J Clin Invest       Date:  2017-11-13       Impact factor: 14.808

7.  The atypical structure and function of newborn arterial endothelium is mediated by Rho/Rho kinase signaling.

Authors:  Sheila Flavahan; Nicholas A Flavahan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-06-20       Impact factor: 4.733

8.  Association of Rho-kinase 1 (ROCK1) gene polymorphisms with Behçet's disease.

Authors:  Elif Oguz; Abdullah Tuncay Demiryürek; Yavuz Pehlivan; Bünyamin Kisacik; Esma Ozkara; Serdar Oztuzcu; Belgin Alasehirli; Ahmet Mesut Onat
Journal:  Mol Diagn Ther       Date:  2014-08       Impact factor: 4.074

9.  Central Rho kinase inhibition restores baroreflex sensitivity and angiotensin II type 1 receptor protein imbalance in conscious rabbits with chronic heart failure.

Authors:  Karla K V Haack; Lie Gao; Alicia M Schiller; Pamela L Curry; Peter R Pellegrino; Irving H Zucker
Journal:  Hypertension       Date:  2013-01-02       Impact factor: 10.190

10.  Release of nonmuscle myosin II from the cytosolic domain of tumor necrosis factor receptor 2 is required for target gene expression.

Authors:  Unni M Chandrasekharan; Lisa Dechert; Uchechukwu I Davidson; Matthew Waitkus; Lori Mavrakis; Katherine Lyons; Jordan R Beach; Xiaoxia Li; Thomas T Egelhoff; Paul L Fox; Paul E DiCorleto
Journal:  Sci Signal       Date:  2013-07-16       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.